{"transactions":[{"id":726208,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-25T22:03:05.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":2324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":2324,"derivative":{"underlying":"Common Stock","underlying_shares":2324},"source":{"system":"sec-edgar","filing":"0001104659-26-077863","document":"tm2619022-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465926077863/tm2619022-2_4seq1.xml","form_type":"4"}},{"id":726207,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-25T22:03:05.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":3691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":3691,"derivative":{"exercise_price":107.55,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":3691},"source":{"system":"sec-edgar","filing":"0001104659-26-077863","document":"tm2619022-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465926077863/tm2619022-2_4seq1.xml","form_type":"4"}},{"id":726206,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-25T22:03:05.000Z","date":"2026-06-23","kind":"exercise","planned":false,"acquired":false,"shares":4712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units are fully vested. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units are fully vested. The restricted stock units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4712},"source":{"system":"sec-edgar","filing":"0001104659-26-077863","document":"tm2619022-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465926077863/tm2619022-2_4seq1.xml","form_type":"4"}},{"id":726205,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T22:03:05.000Z","date":"2026-06-23","kind":"exercise","planned":false,"acquired":true,"shares":4712,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":11712,"source":{"system":"sec-edgar","filing":"0001104659-26-077863","document":"tm2619022-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465926077863/tm2619022-2_4seq1.xml","form_type":"4"}},{"id":739842,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T21:24:26.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":648,"derivative":{"exercise_price":240.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":648},"source":{"system":"sec-edgar","filing":"0001689548-26-000064","document":"wk-form4_1781299464.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000064/wk-form4_1781299464.xml","form_type":"4"}},{"id":739841,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:24:26.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":1371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Mr. Arbuckle was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":2537,"source":{"system":"sec-edgar","filing":"0001689548-26-000064","document":"wk-form4_1781299464.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000064/wk-form4_1781299464.xml","form_type":"4"}},{"id":766431,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true}}],"security":"Stock Option  (Right to Buy)","published_at":"2026-05-22T20:04:48.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":1441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":1441,"derivative":{"exercise_price":298.48,"exercise_date":"2027-05-20","expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":1441},"source":{"system":"sec-edgar","filing":"0001178670-26-000034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000034/form4.xml","form_type":"4"}},{"id":766430,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-22T20:04:48.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":671,"source":{"system":"sec-edgar","filing":"0001178670-26-000034","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000034/form4.xml","form_type":"4"}},{"id":911999,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T21:59:33.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest in equal monthly installments occurring on the 26th day of each month, with the first such installment occurring on February 26, 2026 and the final such installment occurring on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders."}],"balance_after":224,"derivative":{"exercise_price":319.57,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":224},"source":{"system":"sec-edgar","filing":"0001689548-26-000018","document":"wk-form4_1770760770.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000018/wk-form4_1770760770.xml","form_type":"4"}},{"id":911998,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T21:59:33.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Mr. Arbuckle was awarded 478 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":1166,"source":{"system":"sec-edgar","filing":"0001689548-26-000018","document":"wk-form4_1770760770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000018/wk-form4_1770760770.xml","form_type":"4"}},{"id":911997,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T21:59:33.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Mr. Arbuckle was awarded 688 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in two equal annual installments occurring on the first two anniversaries of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":688,"source":{"system":"sec-edgar","filing":"0001689548-26-000018","document":"wk-form4_1770760770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000018/wk-form4_1770760770.xml","form_type":"4"}},{"id":944949,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2026-01-07T21:17:43.000Z","date":"2026-01-05","kind":"grant","planned":false,"acquired":true,"shares":3279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant."}],"balance_after":3279,"derivative":{"exercise_price":397.83,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":3279},"source":{"system":"sec-edgar","filing":"0001735276-26-000005","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000005/edgardoc.xml","form_type":"4"}},{"id":321024,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2025-07-02T20:16:51.000Z","date":"2025-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":37243,"price":450.23,"value":16767915.89,"ownership":{"direct":true},"balance_after":63368,"source":{"system":"sec-edgar","filing":"0000875320-25-000204","document":"wk-form4_1751487400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000204/wk-form4_1751487400.xml","form_type":"4"}},{"id":1100844,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-26T20:37:52.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":4712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":4712,"derivative":{"underlying":"Common Stock","underlying_shares":4712},"source":{"system":"sec-edgar","filing":"0001104659-25-063071","document":"tm2519230-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465925063071/tm2519230-4_4seq1.xml","form_type":"4"}},{"id":1100843,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T20:37:52.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":7037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":7037,"derivative":{"exercise_price":63.66,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":7037},"source":{"system":"sec-edgar","filing":"0001104659-25-063071","document":"tm2519230-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465925063071/tm2519230-4_4seq1.xml","form_type":"4"}},{"id":1103501,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-23T20:51:08.000Z","date":"2025-06-18","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-25-061710","document":"tm2518591-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465925061710/tm2518591-3_4seq1.xml","form_type":"4"}},{"id":1103500,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T20:51:08.000Z","date":"2025-06-18","kind":"exercise","planned":false,"acquired":true,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001104659-25-061710","document":"tm2518591-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465925061710/tm2518591-3_4seq1.xml","form_type":"4"}},{"id":322206,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2025-05-15T20:10:28.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":37622,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 12/06/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 05/13/2025 and the shares will vest on 07/01/2025."}],"balance_after":100611,"source":{"system":"sec-edgar","filing":"0000875320-25-000196","document":"wk-form4_1747339820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000196/wk-form4_1747339820.xml","form_type":"4"}},{"id":325025,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2025-02-28T21:31:03.000Z","date":"2025-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":7071,"price":479.61,"value":3391322.31,"ownership":{"direct":true},"balance_after":62935,"source":{"system":"sec-edgar","filing":"0000875320-25-000124","document":"wk-form4_1740778255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000124/wk-form4_1740778255.xml","form_type":"4"}},{"id":325181,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2025-02-26T21:07:52.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":4716,"price":483.28,"value":2279148.48,"ownership":{"direct":true},"balance_after":70006,"source":{"system":"sec-edgar","filing":"0000875320-25-000105","document":"wk-form4_1740604066.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000105/wk-form4_1740604066.xml","form_type":"4"}},{"id":325788,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2025-02-19T21:25:03.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":2724,"price":463.46,"value":1262465.04,"ownership":{"direct":true},"balance_after":74722,"source":{"system":"sec-edgar","filing":"0000875320-25-000081","document":"wk-form4_1740000293.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000081/wk-form4_1740000293.xml","form_type":"4"}},{"id":326072,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2025-02-14T21:06:26.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":7903,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 02/24/2026."}],"balance_after":77446,"source":{"system":"sec-edgar","filing":"0000875320-25-000059","document":"wk-form4_1739567177.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000059/wk-form4_1739567177.xml","form_type":"4"}},{"id":326175,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2025-02-12T21:26:45.000Z","date":"2025-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":3220,"price":467.98,"value":1506895.6,"ownership":{"direct":true},"balance_after":69543,"source":{"system":"sec-edgar","filing":"0000875320-25-000035","document":"wk-form4_1739395597.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000035/wk-form4_1739395597.xml","form_type":"4"}},{"id":326559,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2025-02-06T21:18:40.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":8448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025."}],"balance_after":72763,"source":{"system":"sec-edgar","filing":"0000875320-25-000009","document":"wk-form4_1738876713.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000009/wk-form4_1738876713.xml","form_type":"4"}},{"id":326558,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2025-02-06T21:18:40.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":14624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025."}],"balance_after":64315,"source":{"system":"sec-edgar","filing":"0000875320-25-000009","document":"wk-form4_1738876713.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000009/wk-form4_1738876713.xml","form_type":"4"}},{"id":1469339,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-25T20:41:15.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-24-074770","document":"tm2418139-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465924074770/tm2418139-6_4seq1.xml","form_type":"4"}},{"id":1469338,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T20:41:15.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":true,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001104659-24-074770","document":"tm2418139-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465924074770/tm2418139-6_4seq1.xml","form_type":"4"}},{"id":1472826,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-21T01:38:51.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-24-073631","document":"tm2417588-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465924073631/tm2417588-1_4seq1.xml","form_type":"4"}},{"id":1472825,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T01:38:51.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":14000,"derivative":{"exercise_price":41.39,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001104659-24-073631","document":"tm2417588-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465924073631/tm2417588-1_4seq1.xml","form_type":"4"}},{"id":333648,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-05-17T20:24:43.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":69,"price":430.93,"value":29734.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":49691,"source":{"system":"sec-edgar","filing":"0000875320-24-000152","document":"wk-form4_1715977463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000152/wk-form4_1715977463.xml","form_type":"4"}},{"id":339127,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-27T21:37:27.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":5034,"price":425.7,"value":2142973.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":49691,"source":{"system":"sec-edgar","filing":"0000875320-24-000099","document":"wk-form4_1709069823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000099/wk-form4_1709069823.xml","form_type":"4"}},{"id":339126,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-27T21:37:27.000Z","date":"2024-02-23","kind":"tax_withholding","planned":true,"acquired":false,"shares":4714,"price":431.79,"value":2035458.06,"ownership":{"direct":true},"balance_after":54725,"source":{"system":"sec-edgar","filing":"0000875320-24-000099","document":"wk-form4_1709069823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000099/wk-form4_1709069823.xml","form_type":"4"}},{"id":339400,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-23T21:12:34.000Z","date":"2024-02-21","kind":"sale","planned":true,"acquired":false,"shares":3603,"price":421.77,"value":1519637.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":59439,"source":{"system":"sec-edgar","filing":"0000875320-24-000087","document":"wk-form4_1708722733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000087/wk-form4_1708722733.xml","form_type":"4"}},{"id":339701,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-21T21:19:22.000Z","date":"2024-02-20","kind":"sale","planned":true,"acquired":false,"shares":4804,"price":420.79,"value":2021475.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":63042,"source":{"system":"sec-edgar","filing":"0000875320-24-000068","document":"wk-form4_1708550288.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000068/wk-form4_1708550288.xml","form_type":"4"}},{"id":339700,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-21T21:19:22.000Z","date":"2024-02-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":3373,"price":420.58,"value":1418616.34,"ownership":{"direct":true},"balance_after":67846,"source":{"system":"sec-edgar","filing":"0000875320-24-000068","document":"wk-form4_1708550288.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000068/wk-form4_1708550288.xml","form_type":"4"}},{"id":339699,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-21T21:19:22.000Z","date":"2024-02-16","kind":"tax_withholding","planned":true,"acquired":false,"shares":4499,"price":424.01,"value":1907620.99,"ownership":{"direct":true},"balance_after":71219,"source":{"system":"sec-edgar","filing":"0000875320-24-000068","document":"wk-form4_1708550288.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000068/wk-form4_1708550288.xml","form_type":"4"}},{"id":340502,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-13T21:51:40.000Z","date":"2024-02-12","kind":"sale","planned":true,"acquired":false,"shares":4295,"price":420.24,"value":1804930.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":75718,"source":{"system":"sec-edgar","filing":"0000875320-24-000043","document":"wk-form4_1707861086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000043/wk-form4_1707861086.xml","form_type":"4"}},{"id":340501,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-13T21:51:40.000Z","date":"2024-02-09","kind":"tax_withholding","planned":true,"acquired":false,"shares":3177,"price":422.74,"value":1343044.98,"ownership":{"direct":true},"balance_after":80013,"source":{"system":"sec-edgar","filing":"0000875320-24-000043","document":"wk-form4_1707861086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000043/wk-form4_1707861086.xml","form_type":"4"}},{"id":1650422,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19597,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650421,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.37,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650420,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.77,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650419,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.56,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650418,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":2.1,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650417,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":11.21,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":15800},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650416,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":11.21,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650415,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4167,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":8.2,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":4167},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650414,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650413,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13090,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":1650412,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T16:41:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5381,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-014706","document":"tm245865-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014706/tm245865-8_4seq1.xml","form_type":"4"}},{"id":341085,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-08T21:23:07.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":8448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/17/2025."}],"balance_after":83190,"source":{"system":"sec-edgar","filing":"0000875320-24-000018","document":"wk-form4_1707427370.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000018/wk-form4_1707427370.xml","form_type":"4"}},{"id":341084,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-08T21:23:07.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":11210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on  02/06/2024 and the shares will vest in installments beginning on 02/10/2024."}],"balance_after":74742,"source":{"system":"sec-edgar","filing":"0000875320-24-000018","document":"wk-form4_1707427370.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000018/wk-form4_1707427370.xml","form_type":"4"}},{"id":341083,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2024-02-08T21:23:07.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":6976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation\ncommittee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024."}],"balance_after":63532,"source":{"system":"sec-edgar","filing":"0000875320-24-000018","document":"wk-form4_1707427370.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000018/wk-form4_1707427370.xml","form_type":"4"}},{"id":1694991,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T17:43:43.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":442,"price":29.65,"value":13105.3,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended December 31, 2023."}],"balance_after":5381,"source":{"system":"sec-edgar","filing":"0001415889-24-000373","document":"form4-01032024_100131.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924000373/form4-01032024_100131.xml","form_type":"4"}},{"id":343621,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-15T21:20:23.000Z","date":"2023-12-13","kind":"exercise","planned":true,"acquired":false,"shares":8603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":8603},"source":{"system":"sec-edgar","filing":"0000875320-23-000056","document":"wk-form4_1702675215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000056/wk-form4_1702675215.xml","form_type":"4"}},{"id":343620,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-12-15T21:20:23.000Z","date":"2023-12-13","kind":"sale","planned":true,"acquired":false,"shares":8603,"price":399,"value":3432597.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":56556,"source":{"system":"sec-edgar","filing":"0000875320-23-000056","document":"wk-form4_1702675215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000056/wk-form4_1702675215.xml","form_type":"4"}},{"id":343619,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-12-15T21:20:23.000Z","date":"2023-12-13","kind":"exercise","planned":true,"acquired":true,"shares":8603,"price":187.53,"value":1613320.59,"ownership":{"direct":true},"balance_after":65159,"source":{"system":"sec-edgar","filing":"0000875320-23-000056","document":"wk-form4_1702675215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000056/wk-form4_1702675215.xml","form_type":"4"}},{"id":1771039,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T17:06:17.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":827,"price":15.87,"value":13124.49,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended September 30, 2023."}],"balance_after":4939,"source":{"system":"sec-edgar","filing":"0001415889-23-013758","document":"form4-10022023_091009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923013758/form4-10022023_091009.xml","form_type":"4"}},{"id":1838227,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T17:54:27.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":695,"price":18.87,"value":13114.65,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 for services performed for the quarter ended June 30, 2023."}],"balance_after":4112,"source":{"system":"sec-edgar","filing":"0001415889-23-010823","document":"form4-07052023_090714.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923010823/form4-07052023_090714.xml","form_type":"4"}},{"id":1844900,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-23T20:30:38.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-23-074290","document":"tm2319485-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465923074290/tm2319485-1_4seq1.xml","form_type":"4"}},{"id":1844899,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T20:30:38.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":14000,"derivative":{"exercise_price":18.47,"expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001104659-23-074290","document":"tm2319485-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557290/000110465923074290/tm2319485-1_4seq1.xml","form_type":"4"}},{"id":348197,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:07:09.000Z","date":"2023-06-15","kind":"exercise","planned":true,"acquired":false,"shares":8603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":8603,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":8603},"source":{"system":"sec-edgar","filing":"0001209191-23-038343","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123038343/doc4.xml","form_type":"4"}},{"id":348196,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-06-20T20:07:09.000Z","date":"2023-06-15","kind":"sale","planned":true,"acquired":false,"shares":8603,"price":349,"value":3002447.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $349.00 (range $349.00 to $349.02)."}],"balance_after":56556,"source":{"system":"sec-edgar","filing":"0001209191-23-038343","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123038343/doc4.xml","form_type":"4"}},{"id":348195,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-06-20T20:07:09.000Z","date":"2023-06-15","kind":"exercise","planned":true,"acquired":true,"shares":8603,"price":187.53,"value":1613320.59,"ownership":{"direct":true},"balance_after":65159,"source":{"system":"sec-edgar","filing":"0001209191-23-038343","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123038343/doc4.xml","form_type":"4"}},{"id":1853414,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:47:41.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":19597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":19597,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001415889-23-009950","document":"form4-06162023_080635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009950/form4-06162023_080635.xml","form_type":"4"}},{"id":1853413,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-06-16T16:47:41.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":13090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."}],"balance_after":13090,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001415889-23-009950","document":"form4-06162023_080635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009950/form4-06162023_080635.xml","form_type":"4"}},{"id":348591,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-06-01T20:16:50.000Z","date":"2023-05-30","kind":"sale","planned":true,"acquired":false,"shares":82,"price":329.82,"value":27045.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023."}],"balance_after":56556,"source":{"system":"sec-edgar","filing":"0001209191-23-033321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123033321/doc4.xml","form_type":"4"}},{"id":1930596,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-04T16:52:04.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":3417,"price":3.84,"value":13121.28,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended December 15, 2022 for services performed for the quarter ended March 31, 2023."}],"balance_after":3417,"source":{"system":"sec-edgar","filing":"0001415889-23-006059","document":"form4-04042023_080455.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923006059/form4-04042023_080455.xml","form_type":"4"}},{"id":352334,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-28T21:47:58.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":800,"price":288.92,"value":231136.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $288.92 (range $288.57 to $289.38)."}],"balance_after":56556,"source":{"system":"sec-edgar","filing":"0001209191-23-013708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013708/doc4.xml","form_type":"4"}},{"id":352333,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-28T21:47:58.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":400,"price":287.59,"value":115036.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $287.59 (range $287.57 to $287.60)."}],"balance_after":57356,"source":{"system":"sec-edgar","filing":"0001209191-23-013708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013708/doc4.xml","form_type":"4"}},{"id":352332,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-28T21:47:58.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":3834,"price":287.16,"value":1100971.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $287.16 (range $286.57 to $287.51)."}],"balance_after":57756,"source":{"system":"sec-edgar","filing":"0001209191-23-013708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013708/doc4.xml","form_type":"4"}},{"id":352331,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-28T21:47:58.000Z","date":"2023-02-24","kind":"tax_withholding","acquired":false,"shares":4714,"price":289.12,"value":1362911.68,"ownership":{"direct":true},"balance_after":61590,"source":{"system":"sec-edgar","filing":"0001209191-23-013708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013708/doc4.xml","form_type":"4"}},{"id":352547,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-24T21:06:38.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":200,"price":296.31,"value":59262.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $296.31 (range $296.20 to $296.41)."}],"balance_after":66304,"source":{"system":"sec-edgar","filing":"0001209191-23-012672","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123012672/doc4.xml","form_type":"4"}},{"id":352546,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-24T21:06:38.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":394,"price":295.38,"value":116379.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $295.38 (range $294.83 to $295.72)."}],"balance_after":66504,"source":{"system":"sec-edgar","filing":"0001209191-23-012672","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123012672/doc4.xml","form_type":"4"}},{"id":352545,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-24T21:06:38.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":1378,"price":294.29,"value":405531.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $294.29 (range $293.83 to $294.82)."}],"balance_after":66898,"source":{"system":"sec-edgar","filing":"0001209191-23-012672","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123012672/doc4.xml","form_type":"4"}},{"id":352544,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-24T21:06:38.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":300,"price":292.86,"value":87858.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $292.86 (range $292.44 to $293.37)."}],"balance_after":68276,"source":{"system":"sec-edgar","filing":"0001209191-23-012672","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123012672/doc4.xml","form_type":"4"}},{"id":352543,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-24T21:06:38.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":129,"price":291.84,"value":37647.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $291.84 (range $291.17 to $292.03)."}],"balance_after":68576,"source":{"system":"sec-edgar","filing":"0001209191-23-012672","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123012672/doc4.xml","form_type":"4"}},{"id":352897,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-22T21:30:12.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":736,"price":294.58,"value":216810.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $294.58 (range $294.36 to $294.96)."}],"balance_after":68705,"source":{"system":"sec-edgar","filing":"0001209191-23-011665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011665/doc4.xml","form_type":"4"}},{"id":352896,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-22T21:30:12.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":1100,"price":293.74,"value":323114.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $293.74 (range $293.30 to $294.19)."}],"balance_after":69441,"source":{"system":"sec-edgar","filing":"0001209191-23-011665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011665/doc4.xml","form_type":"4"}},{"id":352895,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-22T21:30:12.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":545,"price":292.77,"value":159559.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $292.77 (range $292.25 to $293.07)."}],"balance_after":70541,"source":{"system":"sec-edgar","filing":"0001209191-23-011665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011665/doc4.xml","form_type":"4"}},{"id":352894,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-22T21:30:12.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":21,"price":291.01,"value":6111.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."}],"balance_after":71086,"source":{"system":"sec-edgar","filing":"0001209191-23-011665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011665/doc4.xml","form_type":"4"}},{"id":352893,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-22T21:30:12.000Z","date":"2023-02-17","kind":"tax_withholding","acquired":false,"shares":4498,"price":292.85,"value":1317239.3,"ownership":{"direct":true},"balance_after":71107,"source":{"system":"sec-edgar","filing":"0001209191-23-011665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011665/doc4.xml","form_type":"4"}},{"id":353272,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-16T21:14:12.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":400,"price":300.89,"value":120356.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $300.89 (range $300.78 to $301.03)."}],"balance_after":75605,"source":{"system":"sec-edgar","filing":"0001209191-23-010050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010050/doc4.xml","form_type":"4"}},{"id":353271,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-16T21:14:12.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":1734,"price":300.09,"value":520356.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $300.09 (range $299.73 to $300.70)."}],"balance_after":76005,"source":{"system":"sec-edgar","filing":"0001209191-23-010050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010050/doc4.xml","form_type":"4"}},{"id":353270,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-16T21:14:12.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":2003,"price":299.13,"value":599157.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $299.13 (range $298.68 to $299.60)."}],"balance_after":77739,"source":{"system":"sec-edgar","filing":"0001209191-23-010050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010050/doc4.xml","form_type":"4"}},{"id":353269,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-16T21:14:12.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":560,"price":298.14,"value":166958.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $298.14 (range $297.59 to $298.57)."}],"balance_after":79742,"source":{"system":"sec-edgar","filing":"0001209191-23-010050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010050/doc4.xml","form_type":"4"}},{"id":353268,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-16T21:14:12.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":901,"price":296.85,"value":267461.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $296.85 (range $296.49 to $297.30)."}],"balance_after":80302,"source":{"system":"sec-edgar","filing":"0001209191-23-010050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010050/doc4.xml","form_type":"4"}},{"id":353267,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-16T21:14:12.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":800,"price":295.84,"value":236672.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $295.84 (range $295.34 to $296.20)."}],"balance_after":81203,"source":{"system":"sec-edgar","filing":"0001209191-23-010050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010050/doc4.xml","form_type":"4"}},{"id":353538,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-14T21:53:14.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":835,"price":300.13,"value":250608.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $300.13 (range $299.93 to $300.53)."}],"balance_after":82003,"source":{"system":"sec-edgar","filing":"0001209191-23-009182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009182/doc4.xml","form_type":"4"}},{"id":353537,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-14T21:53:14.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":1779,"price":299.26,"value":532383.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $299.26 (range $298.86 to $299.81)."}],"balance_after":82838,"source":{"system":"sec-edgar","filing":"0001209191-23-009182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009182/doc4.xml","form_type":"4"}},{"id":353536,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-14T21:53:14.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":2028,"price":298.42,"value":605195.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $298.42 (range $297.85 to $298.80)."}],"balance_after":84617,"source":{"system":"sec-edgar","filing":"0001209191-23-009182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009182/doc4.xml","form_type":"4"}},{"id":353535,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-14T21:53:14.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":245,"price":296.44,"value":72627.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $296.44 (range $295.84 to $296.57)."}],"balance_after":86645,"source":{"system":"sec-edgar","filing":"0001209191-23-009182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009182/doc4.xml","form_type":"4"}},{"id":353534,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-14T21:53:14.000Z","date":"2023-02-13","kind":"tax_withholding","acquired":false,"shares":5990,"price":298.26,"value":1786577.4,"ownership":{"direct":true},"balance_after":86890,"source":{"system":"sec-edgar","filing":"0001209191-23-009182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009182/doc4.xml","form_type":"4"}},{"id":353533,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-14T21:53:14.000Z","date":"2023-02-10","kind":"tax_withholding","acquired":false,"shares":3372,"price":294.33,"value":992480.76,"ownership":{"direct":true},"balance_after":92880,"source":{"system":"sec-edgar","filing":"0001209191-23-009182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009182/doc4.xml","form_type":"4"}},{"id":354162,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-03T21:36:12.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":11209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/10/2024."}],"balance_after":96252,"source":{"system":"sec-edgar","filing":"0001209191-23-006894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006894/doc4.xml","form_type":"4"}},{"id":354161,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-03T21:36:12.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":14624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023."}],"balance_after":85043,"source":{"system":"sec-edgar","filing":"0001209191-23-006894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006894/doc4.xml","form_type":"4"}},{"id":354160,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2023-02-03T21:36:12.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":12388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023."}],"balance_after":70419,"source":{"system":"sec-edgar","filing":"0001209191-23-006894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006894/doc4.xml","form_type":"4"}},{"id":356032,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2022-12-08T21:08:41.000Z","date":"2022-12-06","kind":"grant","acquired":true,"shares":12753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests on 07/01/2025."}],"balance_after":58031,"source":{"system":"sec-edgar","filing":"0001209191-22-060339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122060339/doc4.xml","form_type":"4"}},{"id":358720,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-17T21:39:29.000Z","date":"2022-08-15","kind":"exercise","acquired":false,"shares":6571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":155.57,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":6571},"source":{"system":"sec-edgar","filing":"0000899243-22-029030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322029030/doc4.xml","form_type":"4"}},{"id":358719,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2022-08-17T21:39:29.000Z","date":"2022-08-15","kind":"sale","acquired":false,"shares":6948,"price":305.38,"value":2121780.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $305.38 (range $305.13 to $305.83)."}],"balance_after":45278,"source":{"system":"sec-edgar","filing":"0000899243-22-029030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322029030/doc4.xml","form_type":"4"}},{"id":358718,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15072,"kind":"person","name":"Arbuckle Stuart A","position":1,"cik":"0001557290","reported_name":"Arbuckle Stuart A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO"}}],"security":"Common Stock","published_at":"2022-08-17T21:39:29.000Z","date":"2022-08-15","kind":"sale","acquired":false,"shares":6990,"price":304.67,"value":2129643.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $304.67 (range $304.13 to $305.12)."}],"balance_after":52226,"source":{"system":"sec-edgar","filing":"0000899243-22-029030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322029030/doc4.xml","form_type":"4"}}],"next_cursor":"2022-08-17T21:39:29.000000Z,358718"}